Good morning, everyone, and welcome to another working week. We hope the weekend — which was a protracted affair for many on this side of the pond — was relaxing and invigorating, because the treadmill has started up again. We could tell as our short person scrambled to leave for the local schoolhouse. As for us, yes, we are quaffing cups of stimulation and invite you to join us. Remember, no prescription is required. And of course, here are some tidbits to help you along. Hope your day is delightful and, as always, to do keep in touch …

The U.S. Supreme Court hears arguments on Monday about whether to halt a system that lets companies ask the U.S. Patent and Trademark Office to challenge patents rather than relying only on courts, Bloomberg News reminds us. Inter partes reviews are designed to be a low-cost alternative to lawsuits, but drug makers complain this uses a different legal standard than courts and is more likely to cancel a patent, depriving them of the right to a jury trial.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy